Drug Trial News

RSS

Phase 3 clinical trial shows favorable safety and immunogenicity profile of single-shot live-attenuated chikungunya vaccine

Researchers performed a double-blinded, phase III randomized trial.

15 Jun 2023

Repeat intraocular corticosteroid injections improve vision in people with persistent or recurrent uveitic macular edema

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a clinical trial funded by the National Eye Institute.

13 Jun 2023

Letermovir: A promising breakthrough in CMV prevention for kidney transplant recipients

In a recent article published in the journal JAMA Network, researchers performed a randomized clinical trial (RCT) to demonstrate the noninferiority of letermovir vs. valganciclovir for prophylaxis of cytomegalovirus (CMV) in adult CMV-seronegative kidney transplant recipients (KTRs) who received a kidney from a CMV-seropositive individual.

13 Jun 2023

VLA1553 vaccine candidate for chikungunya disease produces an immune response in a phase 3 trial

The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.

12 Jun 2023

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.

9 Jun 2023

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

Researchers in the Hermelin Brain Tumor Center at Henry Ford Health are leading a Phase I clinical trial studying the maximum tolerated dose of an oncolytic adenovirus, a mutated virus engineered to selectively replicate in and destroy cancer tissue, in combination with fractionated stereotactic radiosurgery among patients who are undergoing resection of a recurrent high-grade astrocytoma brain tumor.

8 Jun 2023

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

A first-in-class drug engineered to selectively inhibit the signaling pathway of the cannabinoid receptor shows promise as a safe and effective treatment for cannabis use disorder (CUD), a condition where a person is unable to control their cannabis use, even though it's causing problems in their lives.

8 Jun 2023

Targeted therapy for non-small cell lung cancer provides benefit to patients after surgery

A clinical trial led by Yale Cancer Center shows that the drug osimertinib, a targeted therapy for non-small cell lung cancer, improved rates of survival and reduced risk of recurrence in patients after surgery.

7 Jun 2023

Electronic health records identified as hidden source of bias impacting clinical trials

Results of clinical trials are only as good as the data upon which they rest. This is especially true in terms of diversity -; if most people in a trial are from a certain race or socioeconomic group, then the results may not be broadly applicable.

7 Jun 2023

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

7 Jun 2023

Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight

Orally administered semaglutide shows significant efficacy in reducing HbA1c and body weight in patients with type 2 diabetes compared to other treatments. The study includes a large number of participants from multiple trials.

7 Jun 2023

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

Patients with advanced kidney cancer are routinely given immune checkpoint inhibitors (ICIs) as first-line treatment.

5 Jun 2023

HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clinical benefit in several tumor types

In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types.

5 Jun 2023

Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel

Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

5 Jun 2023

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations.

5 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.

4 Jun 2023

Study of immunotherapy for brain cancer metastases shows promising results

Previous
1
...
10
11
12
13
14
15
16
...
1135
Next

Drug Trial News

Phase 3 clinical trial shows favorable safety and immunogenicity profile of single-shot live-attenuated chikungunya vaccine

Repeat intraocular corticosteroid injections improve vision in people with persistent or recurrent uveitic macular edema

Letermovir: A promising breakthrough in CMV prevention for kidney transplant recipients

VLA1553 vaccine candidate for chikungunya disease produces an immune response in a phase 3 trial

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

Targeted therapy for non-small cell lung cancer provides benefit to patients after surgery

Electronic health records identified as hidden source of bias impacting clinical trials

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clinical benefit in several tumor types

Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Study of immunotherapy for brain cancer metastases shows promising results

Lupus Therapeutics announces three Phase 3 clinical trials testing new therapies for SLE and lupus nephritis

Eye drops to slow the progression of nearsightedness in kids could be on the horizon

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News